EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review

Francesca Gavaruzzi, Guido Granata iD, Alessandro Capone, Pierangelo Chinello, Stefania Cicalini iD

Antibiotics · 07.11.2025 · 14 (11) · 1130

DOI: 10.3390/antibiotics14111130 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 07.11.2025. Verfasst von Francesca Gavaruzzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectiou…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dalbavancin and oritavancin are long-acting lipoglycopeptides increasingly used off-label for a variety of Gram-positive infections. While their efficacy has been described in osteomyelitis, bacteremia, and infective endocarditis, evidence specifically addressing cardiovascular prosthetic infections such as prosthetic valve endocarditis (PVE), cardiac implantable electronic device (CIED) infections, left ventricular assist device infections (LVAD), and prosthetic vascular graft infections (PVGI) remains limited. These conditions are particularly challenging due to biofilm formation, difficulties in achieving surgical source control, and the frequent need for prolonged or suppressive therapy.

Objectives

This systematic review aimed to summarize the available literature on the use of dalbavancin and oritavancin in cardiovascular prosthetic infections, with a focus on therapeutic strategies, clinical outcomes, and safety.

Methods

We performed a systematic search of PubMed, Embase, Scopus, and Cochrane Library up to 24 June 2025 in accordance with PRISMA guidelines. Eligible studies included adults treated with dalbavancin or oritavancin for cardiovascular prosthetic infections. Data on study characteristics, population demographics, causative pathogens, and microbiological profiles, antibiotic regimens, treatment duration, use of therapeutic drug monitoring (TDM), indication or non-indication for chronic suppressive therapy, adverse events, clinical outcomes, and clinical efficacy were extracted.

Results

Twenty studies comprising 113 patients were identified, of whom 111 received dalbavancin and 2 oritavancin. The main infections were PVE, CIED, LVAD, and PVGI. Dalbavancin was most effective as consolidation therapy after surgery or device removal, with high cure rates. Prolonged regimens were used as bridging or in partially treated cases, sometimes supported by TDM or PET/CT. Chronic suppressive therapy, mainly for LVAD and PVGI infections, achieved variable outcomes with relapses in about one fifth of patients. Adverse events were infrequent and generally mild.

Conclusions

The included studies were highly diverse, conducted in various settings and with different objectives. Eight of the twenty included studies were single case reports on dalbavancin and oritavancin, highlighting the predominance of individual case descriptions in the available literature. Long-acting lipoglycopeptides may represent a valuable option for cardiovascular prosthetic infections. Their role appears most favorable as consolidation after adequate source control, while chronic suppressive use showed heterogeneous outcomes. This systematic review was registered on Open Science Framework. This work was supported by grants from the Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3.

Schlagwörter

Stichwörter der Autor:innen

cardiac implantable electronic device infectionscardiovascular infectionscardiovascular prosthetic infectionschronic suppressive antibiotic therapydalbavancinendocarditis outcomeleft ventricular assist device infectionslong-acting lipoglycopeptide antibioticsmortalityoritavancinprosthetic valve endocarditissource controlvascular prostheses infections

Autor:innen und Institutionen

  • Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

ORCID-Profile: Guido Granata, Stefania Cicalini

Förderung

  • Italian Ministry of Health
  • Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3

Zitieren

APA

Gavaruzzi, F., Granata, G., Capone, A., Chinello, P., & Cicalini, S. (2025). Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review. Antibiotics, 14(11), 1130. https://doi.org/10.3390/antibiotics14111130

Vancouver

Gavaruzzi F, Granata G, Capone A, Chinello P, Cicalini S. Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review. Antibiotics. 2025;14(11):1130. doi:10.3390/antibiotics14111130

BibTeX
@article{Gavaruzzi2025,
  author = {Gavaruzzi, Francesca and Granata, Guido and Capone, Alessandro and Chinello, Pierangelo and Cicalini, Stefania},
  title = {Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review},
  journal = {Antibiotics},
  year = {2025},
  volume = {14},
  number = {11},
  pages = {1130},
  doi = {10.3390/antibiotics14111130}
}
Kostenlos starten →